Addressing Health Care Disparities and Improving Patient Outcomes in Prostate Cancer: Expert Perspectives on Optimizing ADT

Jointly provided by

     

Support for this activity has been provided through an educational grant from Pfizer Inc and Myovant Sciences Ltd.

Release date: 3/13/2023

Expiration date:  3/13/2024

Estimated time to complete: 0.75 hour

Overview

Prostate cancer is the leading cause of cancer and the second leading cause of cancer death in men in the United States. Medical androgen deprivation therapy (ADT) is the standard of care for advanced prostate cancer but may be associated with a broad range of adverse effects. Increased risk of cardiovascular (CV) events is among the most serious, as CV disease is the most common non-cancer cause of death in prostate cancer patients. Although evidence-based guidelines on ADT selection and CV risk mitigation are available, research has shown that many health care providers (HCPs) are unable to effectively mitigate CV risk in patients receiving ADT for advanced prostate cancer.

Studies also indicate that socioeconomic factors and differences in patterns of care contribute to disparities in prostate cancer outcomes. This is a problematic trend with significant implications for prostate cancer patients who are US Veterans and/or Black, who are at substantially greater risk for worse outcomes due to inequities in care.

This activity has been developed to enhance HCPs’ knowledge and competence regarding selection of appropriate ADT, assessment and management of CV risk, and methods to overcome racial and socioeconomic disparities in advanced prostate cancer care.

Faculty

Alicia K. Morgans, MD, MPH—Program Co-Chair
Genitourinary Medical Oncologist
Medical Director, Survivorship Program
Dana-Farber Cancer Institute
Boston, Massachusetts

Neal Shore, MD, FACS—Program Co-Chair
Chief Medical Officer
Urology/Surgical Oncology, GenesisCare
Myrtle Beach, South Carolina

Target Audience

This activity has been designed to meet the educational needs of urologists, medical and radiation oncologists, advanced practice practitioners, and other HCPs who treat patients with advanced prostate cancer, especially clinicians practicing in communities with high Veteran and Black patient populations.

Learning Objectives

Upon completion of this activity, participants should be better able to:

  • Outline the prevalence and disparities in equitable care for US Veterans and Black men with prostate cancer
  • Evaluate the benefits and limitations of available ADT options (luteinizing hormone–releasing hormone [LHRH] agonists, gonadotropin-releasing hormone [GnRH] agonists and antagonists) for patients with advanced prostate cancer according to clinical efficacy, CV risk, mechanism of action, and route of administration
  • Assess and mitigate CV risk in patients receiving ADT for advanced prostate cancer
  • Design an individualized treatment plan that includes the most appropriate ADT according to patient preferences and addresses barriers to equitable care for US Veterans and Black men with advanced prostate cancer

Accreditation and Credit Designation

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the University of Cincinnati, the Veterans Health and Wellness Foundation, and RedMedEd. The University of Cincinnati is accredited by the ACCME to provide continuing medical education for physicians.

Physician Credit Designation Statement (AMA)

The University of Cincinnati designates this enduring material for a maximum of 0.75 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure

In accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education and the University of Cincinnati policy, all faculty, planning committee members, and other individuals who are in a position to control content are required to disclose all relationships with ineligible companies (commercial interests) within the last 24 months. All educational materials are reviewed for fair balance, scientific objectivity, and levels of evidence. The ACCME requires us to disqualify from involvement in the planning and implementation of accredited continuing education any individuals (1) who refuse to provide this information or (2) whose conflicts of interests cannot be mitigated.

All of the relevant financial relationships listed for these individuals have been mitigated. The following disclosures were made:
Alicia K. Morgans, MD, MPH, has disclosed the following relevant financial relationships:
Consulting: AAA, Astellas, AstraZeneca, Bayer, Dendreon, Exelixis, Janssen, Lantheus, Myriad, Myovant, Novartis, Pfizer, Sanofi, Telix
Research: Astellas, Bayer, Dendreon, Myovant, Pfizer, Sanofi

Neal Shore, MD, FACS, has disclosed the following relevant financial relationships:
Consulting: AbbVie, Alessa Therapeutics, Arquuer, Asieris, Astellas, AstraZeneca, Bayer, Bristol Myers Squibb, Boston Scientific, Clarity, Cold Genesys, Dendreon, Ferring, Foundation Medicine, ImmunityBio, Incyte, Invitae, Janssen, Lantheus, Lilly, Merck, Minoic, Myovant, Myriad, NGM, Nonagen, Novartis, Photocure, Pfizer, Promaxoa, Protara, Sanofi, Sesen Bio, Telix, Tolamr, Vaxxion
Board: Photocure

University of Cincinnati
Faculty and staff involved in the development and review of this activity have disclosed no relevant financial relationships.

Veterans Health and Wellness Foundation
Evelyn L. Lewis, MD, MA, FAAFP, DABDA, has disclosed the following relevant financial relationships:
Consulting: Chroma

RedMedEd
The RedMedEd planners have disclosed no relevant financial relationships.

Unapproved Product Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. The University of Cincinnati, the Veterans Health and Wellness Foundation, RedMedEd, and Pfizer Inc and Myovant Sciences Ltd do not recommend the use of any agent outside the labeled indications.

Disclaimer

The information presented in this activity is for continuing medical education purposes only and is not meant to substitute for the independent medical judgment of a physician regarding diagnosis and treatment of a specific patient’s medical condition.

The opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of the University of Cincinnati, the Veterans Health and Wellness Foundation, RedMedEd or Pfizer Inc and Myovant Sciences Ltd. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Method of Participation

There are no fees to participate in the activity. Participants must review all activity information, including the learning objectives, disclosure statements, and content. To receive CME credit, participants must complete the posttest and program evaluation. Certificates can be printed immediately.

Contact Information

For questions regarding CME credit, contact the University of Cincinnati at uc-cloudcme@ucmail.uc.edu.
For technical questions related to this activity, please contact RedMedEd at 610.251.6841 or education@redmeded.com.

Hardware/Software Requirements

  • iPad, iPad Mini (iPadOS 14 or higher), iPhone (iOS 14 or higher), or Android device (OS 11 or higher) with an Internet connection
    • Internet browsers: Chrome, Firefox, Safari
  • A computer with an Internet connection
    • Internet browsers (PC): Chrome, Firefox, Microsoft Edge
    • Internet browsers (Mac): Chrome, Firefox, Safari

Privacy

This website is managed by RedMedEd, and RedMedEd’s printed privacy policy applies to this site. CME credit for this activity is provided by the University of Cincinnati. If you register for CME credit for this educational activity, RedMedEd will forward relevant personally identifiable information to the University of Cincinnati so that records can be maintained concerning any credits issued to you. Aggregated data concerning registrations, posttests, and evaluations may be shared, but RedMedEd will not knowingly share any personally identifiable information. The information you provide on this site may be used to contact you about your CME credit or other relevant educational activities provided through the University of Cincinnati or RedMedEd. For more information, contact uc-cloudcme@ucmail.uc.edu or education@redmeded.com.

For more information about the privacy policy of the University of Cincinnati, please visit https://uc.cloud-cme.com.

Copyright

© 2023. This CME/CE-certified program is held as copyrighted by the University of Cincinnati, the Veterans Health and Wellness Foundation, and RedMedEd. Through this notice, the University of Cincinnati, the Veterans Health and Wellness Foundation, and RedMedEd grant permission of its use for educational purposes only. These materials may not be used, in whole or in part, for any commercial purposes without prior permission in writing from the copyright owners.